Company presentation – Full year 2017












SOL Group at a glance

- Founded in 1927, is an Italian based multinational company present in 28 countries with more of 3,500 people employed.
- Two core, separated but integrated and synergic business areas: Technical Gas sector (production, applied research and marketing of pure, medical and industrial gases) and Home-Care service sector (supply of medical products and medical assistance services as well as equipment for home care therapy).
- Two recent businesses: Hydro Energy and Biotechnology.
- Strong results and sound balance sheet:
 - Over 756 millions € of Total Group revenues in FY2017 (+7.6% FY2016);
 - Over 54% of international revenues in 2017 (vs 23.7% in 2000)
 - 5.9% sales CAGR in the last 10 years;
 - 22.1% of EBITDA margin in 2017;
 - 0.503 of Debt/Equity ratio;
 - Dividend policy: 30% average dividend pay out ratio over the last 10 years.



SOL Group – Geographic Presence



The Technical Gases Business





The Technical Gases Business

SOL Group operates in the technical gases business throughout the brand SOL

Production and distribution of Gases

A complete range of industrial gas (both atmospheric and non-atmospheric): medicinal, pure and special gases.

- Oxygen
- Nitrogen
- Argon
- Hydrogen
- Carbon dioxide
- Acetylene
- Nitrous oxide
- **Gas mixtures**

- Ultra high purity gases
- Medical gases Gaseous helium
- Liquid helium
- Refrigerating gases
- Electronics gases
- Ammonia
- Combustible e gases

Supply of plants, equipments, services and consultancy

Research, design, and construction of:

- Industrial gas production facilities,
- Plant and equipment for gas utilization
- **Services and consultancy**

- **Equipment for medical applications**
- Equipment for cryogenic applications On-site plants
- Deep freezing tunnels
- Oxygen burners
- Ozonisers

- Medical air plants
- Welding machines and equipment



Technical Gases Business

Technical gases business (M€)	FY2017	FY2016	YoY
Sales	398	373	+ 6.8%
EBITDA	73	76	- 3.7%
EBITDA %	18.4%	20.3%	
Investments	52	57	

- In 2017 the division invested over the 13% of its revenues.
- . 3.0% sales CAGR over the last 10 ys.







Technical Gases business


Market characteristics


- Resilient and growing market
- Margin protected thanks to high entry barriers
- Limited economic cycle demand dependence of each sales area
 - Broad variety and diversification of end-markets and applications
- Medium/long term contracts
- Local presence as a key factor

SOL

- High diversification of sales area:
 - More than 50,000 clients served;
 - More than 90 different applications for technical gases
- Long term contracts with customers:
 - Gas pipeline: up to 15 years;
 - Compressed gases: up to 5 years;
 - Cryogenic liquid gases: up to 3 years
- Strong local presence:
 - 25 countries, 38 primary transformation plants, 56 secondary transformation plants.









The Home Care Business





The Home Care Business

- In the second half of the eighties, SOL seized a new market diversification opportunity by entering into the Home-Care service sector, synergical with the technical gas sector.
- The Group works through the VIVISOL Group, which supplies technologically advanced home care services to patients for the treatment of chronic pathologies.
- VIVISOL manages the complete patient care from the delivery of medical equipment and drugs, performed by specialized home care professionals, to the provision of qualified medical and nursing services, as well as tele-monitoring services and emergency management.
- The company operates in 13 leading countries in Europe, in Brazil and Turkey, with over 60 offices employing over 1.800 employees and serving more than 370.000 patients daily.





The Home Care Business

Home care respiratory assistance

- Long term oxygen therapy
- Mechanical ventilation therapy
- Assistance to patients undergoing oxygen therapy during travels (VIVITRAVEL)
- Diagnosis and treatment of sleep disorder conditions

Other home care assistance

- Home care artificial nutrition
- Integrated home care services
- Remote monitoring and diagnosis of respiration conditions
- Palliative Care





Home Care Business

Hone Care business (M€)	FY2017	FY2016	YoY
Sales	388	360	+ 7.9%
EBITDA	94	92	+ 2.6%
EBITDA %	24.2%	25.5%	
Investments	41	41	

- in 2017, with an EBITDA margin higher than 24%.
- The Group is continuing to invest significantly in this business.







Home Care Business



Key growth drivers:

- Aging population demographics
- Restructuring of Health Care Systems through de-hospitalization and home care
- Developments in portable medical technologies
- Better quality of life for Patients at home
- Increasing of respiratory and chronic pathologies





Home Care - VIVISOL branches



Home Care Business





The Hydro Energy Business





The Hydro Energy Business

- Leveraging on its core business development in the Eastern Europe, SOL entered into the Hydro-Energy sector.
- The industrial gas sector, is one of the most energy intensive one. This characteristic supported the Group decision to invest in the Hydro-Energy sector in order to enjoy synergies with its Industrial Gases Business.





Currently the company owns and operates 5 hydro-electric power plants in Slovenia (about 50 Million KWh/year), 2 plants in Albania (about 25 Million KWh/year); 4 plants in Macedonia (about 35 Million KWh/year); 4 plants in Bosnia (about 6 Million KWh/year).



The Biotechnology Business





The Biotechnology Business


- SOL Group is active in supplying biotechnological equipment and services to hospitals, clinics and laboratories (cryobanks, cellfactories, cryomanagement, cryotransportation)
- With BIOTECHSOL is active in the area of tissue and stem cells banking and biological tissues transportation.
- With the acquisition of the majority of DIATHEVA, SOL Group is active in drug discovery and drug delivery (recombinant monoclonal antibodies), molecular diagnostic, GMP production of recombinant proteins










SOL Group: 30 years Turnover (1987-2017)




SOL Group: consolidated results (2007 – 2017)










10 years net profit and dividend growth

NET PROFIT

DPS - Dividend Yield



10Y AVERAGE PAY-OUT RATIO 30%



International Expansion

10 years sales outside Italy 2007-2017



SOL is focused on its international expansion:

- The Group started its operations in Italy where it currently has 15 primary production sites.
- In 2017 the Group is present in 28 countries.
- In 2017 the non-domestic sales exceeded the Italian sales
- . (54% / 46%).



Capital Expenditures (2007-2017)

10 years of investments on sales 2007-2017




High annual investments

- The Group every year invest about 14% of its revenues;
- The Sol business require a high level of investments for long term growth options;
- In 2017 almost the 60% of the Group investments was made outside Italy.



Shareholding information and market price



Source: Bloomberg

Outstanding Shares

- 90.700.000 ordinary shares
- par value: 0,52

Shareholding Structure

- Fumagalli and Annoni families 60%
- Main Institutional Investors:
 - Tweedy Brown 7,346%
 - J O Hambro 5,072%
 - azValor 3,788%











